Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

NCT00091078 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

NIH

Sponsor class

Conditions

Gastrointestinal Stromal Tumor

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)